FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

Post-Surgery Recovery Stack

Recovery & Healingintermediate
42
Share
Peptidi

3

Media giornaliera mcg

2,629

Livello

intermediate

Aggiunto

May 16, 2026

Panoramica

The Post-Surgery Recovery Stack is a targeted tissue repair protocol engineered to accelerate healing timelines following surgical procedures. This intermediate-level stack combines three peptides with complementary mechanisms that address wound healing, inflammation management, and tissue remodeling simultaneously. BPC-157, administered at 500mcg twice daily, forms the foundation of this recovery protocol. This 15-amino-acid peptide, originally isolated from human gastric juice, has demonstrated remarkable wound-healing properties in numerous preclinical studies. It accelerates angiogenesis, promotes fibroblast migration to wound sites, and upregulates growth factor receptors including VEGF and EGF. The twice-daily dosing maintains consistent tissue-level concentrations throughout the healing process, supporting continuous repair signaling around the clock. TB-500, dosed at 5000mcg twice weekly, provides the structural scaffolding for tissue regeneration. As a synthetic fragment of Thymosin Beta-4, it promotes cellular migration by upregulating actin polymerization, allowing repair cells to reach damaged tissue more efficiently. TB-500 also reduces scar tissue formation by modulating inflammatory cytokines during the proliferative phase of wound healing, resulting in more functional tissue restoration rather than fibrotic repair. GHK-Cu at 200mcg daily rounds out the stack with its powerful tissue-remodeling properties. This copper-binding tripeptide stimulates collagen synthesis, attracts immune cells for debris clearance, and promotes nerve regeneration. Research has shown GHK-Cu activates over 4,000 genes involved in tissue repair and remodeling, making it an exceptionally broad-spectrum healing agent. This stack is ideal for individuals recovering from orthopedic surgeries, cosmetic procedures, or any operation involving significant tissue disruption. It is recommended to begin the protocol 3-5 days post-surgery once initial hemostasis is established. BPC-157 injections are most effective when administered near the surgical site subcutaneously. A typical cycle runs 6-8 weeks, aligning with standard surgical recovery windows. Bloodwork monitoring is recommended but not strictly required at this intermediate level.

Protocollo di Dosaggio

BPC-157

Twice per day

Leggi di più su BPC-157 →

500 mcg

per dose

TB-500

Twice per week

Leggi di più su TB-500 →

5,000 mcg

per dose

200 mcg

per dose

Obiettivi & Evidenze

Livello di Evidenza:community

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.